Friday, 23 Aug 2019

You are here

Tofacitinib Efficacy Revealed in OPAL Study

Pfizer has issued a press release of its preliminary results from the OPAL study that examined the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adults active psoriatic arthritis (PsA).

422 PsA patients, on background DMARD therapy, were randomized to receive tofacitinib (5 mg or 10 mg BID), adalimumab 40 mg q2 wk (active control) or  placebo in a phase III trial.

The primary efficacy endpoint was met with ACR20 responses for both tofacitinib 5 mg BID and 10 mg BID being superior to placebo at 3 months. Disappointingly, no numeric results were released for comparison and magnitude of benefit.

These presumeably positive results in PsA contrast the less-than-expected results in psoriasis only patients, where recent clinical trials demonstrated that tofacitinib 5 mg bid was inferior to etanercept, but 10 mg bid was equal to etanercept in PASI 75 responses.
 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Skyrizi Outduels Humira in Psoriasis

A head-to-head trial has shown that risankizumab was significantly superior to adalimumab in providing skin clearance (PASI90) in patients with moderate-to-severe plaque psoriasis, with no difference in safety signals between the two agents.

Biologic Therapy Improves Psoriasis and Reduces CV Inflammation

Psoriasis confers a significant risk of comorbidity, but is psoriasis associated with increased coronary inflammation and is this risk attenuated by biologic therapy? JAMA Cardiology has published a cohort study of 134 consecutive patients with moderate to severe psoriasis, showing that biologic therapy was associated with a significant decrease in coronary inflammation as assessed by perivascular fat attenuation index, a marker of coronary inflammation associated with cardiovascular outcomes. Patients not receiving biologic therapy had no change in perivascular fat attenuation index at 1 year.

Joint Surgery Rates Remain High in Psoriatic Arthritis

The incidence rate of joint surgery among patients with psoriatic arthritis (PsA) has remained persistently high, double that of the general population, according to a new Danish cohort study.

Fatigue is Driven by Inflammation, Pain, and Chronicity in Psoriatic Arthritis

Correlates with fatigue were assessed in psoriatic arthritis (PsA) patients in the DANBIO registry and found to be associated with  clinical inflammatory factors, disease duration, and chronic pain.

A toital of 2062 PsA patients in the Danish nationwide registry DANBIO were studied by cross-sectional survey from December 2013 to June 2014.

CAM Use is Common in Psoriasis

The July issue of the Journal of the American Academy of Dermatology reports that patients with psoriasis are frequent users of complementary and alternative medicines (CAMs) largely because of disatisfaction with traditional medications.

The National Psoriasis Foundation commissioned a survey of patients on CAMs use and patients' perceptions.

The survey was sent to 100,927 NPF members and 219 completed it.